ReviewPolish journal of microbiology
Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties.
Review in Polish journal of microbiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 200 citations in OpenAlex.
- Complete Genome Sequencing of Streptomyces sp. Qhu-M197 Isolated from Alpine Meadows in the Qinghai-Tibetan Plateau Uncovers Biosynthetic Gene Clusters Encoding Bioactive Natural Products.Biochemical genetics · 2026Article
- Screening and identification of a new antimicrobial,RSC advances · 2026Article
- Symbiotic Bacterial Diversity, Functional Profiling and Antibiotic Susceptibility of the Red Imported Fire Ant.Microorganisms · 2026Article
- Boron's Double Edge-Antibiotics, Toxins, and the Fine Line Between Them.Molecules (Basel, Switzerland) · 2026Review
- Actinomycetes in the spotlight: biodiversity and their role in bioremediation.World journal of microbiology & biotechnology · 2026Review
- Plant Endophytes and their Secondary Metabolites: A Source of Bioactive Compounds.Current drug research reviews · 2026Review
- In Vitro Evaluation of the Antiviral Effect ofViruses · 2025Article
- Functional genomics and phenotypic characterization of PGP and biocontrol traits of rhizospheric Streptomyces spp. from Mexican milpa agroecosystem.BMC microbiology · 2025Article
- Mechanism, Efficacy, and Safety of Natural Antibiotics.Antibiotics (Basel, Switzerland) · 2025Review
- Isolation of a NovelToxins · 2025Article
- Aglycone Polyether Ionophores Affecting Actin Filaments as Broad-Spectrum Antiviral Agents.ACS pharmacology & translational science · 2025Article
- Strategies Used for the Discovery of New Microbial Metabolites with Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Review
- Inhibitory Activity of Compounds Obtained fromPathogens (Basel, Switzerland) · 2025Article
- Biocontrol of Agroathelia rolfsii associated with stem rot disease in tomato (Solanum lycopersicum L.) and growth promotion using compost-associated actinobacteria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Exploring new natural products by utilizing untapped secondary metabolic pathways in actinomycetes.Journal of natural medicines · 2025Review
- Diversity of secondary metabolites from marine Streptomyces with potential anti-tubercular activity: a review.Archives of microbiology · 2025Review
- Antimicrobial Lobophorins from Endophytic StrainMolecules (Basel, Switzerland) · 2025Article
- Bioactive Angucyclines/Angucyclinones Discovered from 1965 to 2023.Marine drugs · 2025Review
- Characteristics and differences in immune response capacity and gut microbiome between wild and captive Amur grayling (Frontiers in immunology · 2025Article
- An Integrated Computational Approach to Identify Potent HIV-1 Protease Inhibitors from Marine Sources.Combinatorial chemistry & high throughput screening · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing resistance of microorganisms towards antibiotics has become a serious global problem. Therapeutics with novel chemical scaffolds and/or mechanisms of action are urgently needed to combat infections caused by multidrug resistant pathogens, including bacteria, fungi and viruses. Development of novel antimicrobial agents is still highly dependent on the discovery of new natural products. At present, most antimicrobial drugs used in medicine are of natural origin. Among the natural producers of bioactive substances, Actinobacteria continue to be an important source of novel secondary metabolites for drug application. In this review, the authors report on the bioactive antimicrobial secondary metabolites of Actinobacteria that were described between 2011 and April 2018. Special attention is paid to the chemical scaffolds, biological activities and origin of these novel antibacterial, antifungal and antiviral compounds. Arenimycin C, chromopeptide lactone RSP 01, kocurin, macrolactins A1 and B1, chaxamycin D as well as anthracimycin are regarded as the most effective compounds with antibacterial activity. In turn, the highest potency among selected antifungal compounds is exhibited by enduspeptide B, neomaclafungins A-I and kribelloside D, while ahmpatinin i Bu, antimycin A1a, and pentapeptide 4862F are recognized as the strongest antiviral agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.